[go: up one dir, main page]

WO2016006975A2 - Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation - Google Patents

Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation Download PDF

Info

Publication number
WO2016006975A2
WO2016006975A2 PCT/KR2015/007220 KR2015007220W WO2016006975A2 WO 2016006975 A2 WO2016006975 A2 WO 2016006975A2 KR 2015007220 W KR2015007220 W KR 2015007220W WO 2016006975 A2 WO2016006975 A2 WO 2016006975A2
Authority
WO
WIPO (PCT)
Prior art keywords
piperazin
methylimidazo
difluoro
triazin
phenyl
Prior art date
Application number
PCT/KR2015/007220
Other languages
English (en)
Other versions
WO2016006975A3 (fr
Inventor
Jung Nyoung Heo
Hwan Jung LIM
Kwang Rok Kim
Kyung Jin Kim
Uk Il Kim
Hyung Tae Bang
Ji Hye Yoon
Original Assignee
St Pharm Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020150068368A external-priority patent/KR20160007347A/ko
Application filed by St Pharm Co., Ltd. filed Critical St Pharm Co., Ltd.
Priority to EP15818456.4A priority Critical patent/EP3166946A4/fr
Priority to US15/325,692 priority patent/US10179785B2/en
Publication of WO2016006975A2 publication Critical patent/WO2016006975A2/fr
Publication of WO2016006975A3 publication Critical patent/WO2016006975A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to a novel imidazotriazinone or imidazopyrazinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.
  • PARPs constitute a family of cell signaling enzymes present in eukaryotes which catalyze poly(ADP-ribosylation) (PARsylation) of DNA-binding proteins and other substrate proteins. PARPs are also known as poly(ADP-ribose) synthases or poly(ADP-ribose) transferases (pARTs). Some PARPs also transfer single ADP-ribosyl-moieties. These enzymes, for example, play an important role in the immediate cellular response to DNA damage.
  • PARPs In response to DNA damage induced by ionizing radiation, oxidative stress and DNA-binding anti-tumor drugs, PARPs add ADP-ribose units to the carboxylate groups of aspartic and glutamic residues of target proteins.
  • This poly(ADP-ribosylation) is a post-translational modification process that triggers the inactivation of the acceptor protein through the attachment of a complex branched by a polymer of ADP-ribose units.
  • ADP ribosylation is a post-translational protein modification process in which the ADP-ribose moiety is transferred from NAD onto specific amino acid side chains of target proteins (Schreiber et al. , 2006, Nature Reviews Cell Biology , 7: 517-528).
  • PARP family proteins are promising therapeutic targets. PARP1 and PARP2 play a role in DNA damage responses and PARP inhibitors sensitize cancer cells for drug and radiation therapies. In addition, PARP1 has been linked to other diseases including inflammation, neuronal cell death and ischemia. Tankyrases (TNKS1 and TNKS2), which share high sequence similarity with PARP1, are also emerging therapeutic targets. Tankyrases were initially known as regulators of telomerase activity and are involved in DNA damage responses and Wnt signaling (Wahlbert et al. , 2012, Nat. Biotechnol . , 30(3): 283-288).
  • the tankyrase protein family consists of tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2) which share 85% amino acid identity.
  • Biological functions of both tankyrase 1 and tankyrase 2 were studied in genetically engineered mice lacking mouse tankyrase 1 and/or tankyrase 2.
  • Tankyrase 2-deficient mice developed normally and showed no detectable change in telomere length, but did show a significant decrease in total body weight that might reflect a role of tankyrase 2 in glucose or fat metabolism. No defects in telomere length maintenance were detected in tankyrase 1-deficient mice. However, in double-knockout mice lacking both tankyrase 1 and tankyrase 2 embryonic lethality was observed on embryonic day 10 (Chiang et al. , 2008, PLoS One , 3(7): e2639).
  • a key feature of the Wnt/ ⁇ -catenin pathway is the regulated proteolysis of the downstream effector ⁇ -catenin by the ⁇ -catenin destruction complex.
  • the principal constituents of a ⁇ -catenin destruction complex are adenomatous polyposis coli (APC), axin and GSK3 ⁇ / ⁇ .
  • APC adenomatous polyposis coli
  • cytosolic ⁇ -catenin is constitutively phosphorylated and targeted for degradation.
  • a ⁇ -catenin destruction complex is dissociated, which leads to accumulation of ⁇ -catenin in the nucleus and transcription of Wnt pathway responsive genes.
  • a tankyrase inhibitor selectively inhibits the transcription mediated by ⁇ -catenin by promoting ⁇ -catenin degradation through stabilization of axin (Huang et al. , 2009, Nature , 461(7264): 614-620).
  • Axin1 and Axin2 mutations have been identified in patients with hepatocarcinomas and colorectal carcinomas (Taniguchi et al. , 2002, Oncogene , 21: 4863-4871; Liu et al. , 2000, Nat. Genet. , 26: 146-147). These somatic mutations result in Wnt-independent stabilization of ⁇ -catenin and constitutive activation of ⁇ -catenin-mediated transcription.
  • deregulated Wnt pathway activity has also been implicated in many other non-cancer diseases including osteoporosis, osteoarthritis, polycystic kidney disease, pulmonary fibrosis, diabetes, schizophrenia, vascular diseases, cardiac diseases, non-oncogenic proliferative diseases, neurodegenerative diseases such as Alzheimer's disease, etc.
  • Therapeutics which are directed to and can correct dysregulation of the Wnt signaling pathway have been implicated in conditions such as bone density defects, coronary disease, late-onset Alzheimer's disease, familial exudative vitreoretinopathy, retinal angiogenesis, tetraamelia, Muellerian-duct regression and virilization, Serkal syndrome, type 2 diabetes, Fuhrmann syndrome, skeletal dysplasia, focal dermal hypoplasia and neural tube defects.
  • the Wnt signaling pathway is of fundamental importance in a broad range of human diseases, not necessarily being limited to the examples provided above for illustrative purposes.
  • tankyrase-1 and -2 would also be expected to have an effect on other biological functions of tankyrase proteins (e.g., chromosome end (telomere) protection, insulin responsiveness and spindle assembly during mitosis) (Chang et al. , 2005, Biochem . J. , 391: 177-184; Chi et al. , 2000, J. Biol. Chem . , 275: 38437-38444; Bae et al. , 2003, J. Biol. Chem. , 278: 5195-5204).
  • chromosome end (telomere) protection e.g., insulin responsiveness and spindle assembly during mitosis
  • the present invention provides a compound represented by Chemical Formula 1, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof:
  • V is N or CH
  • R 1 is hydrogen, C 1-6 alkyl, C 1-6 hydroxyalkyl, or C 1-6 dihydroxyalkyl;
  • each of W and X is independently CHR 4 or CO;
  • Y is N or C
  • l 0, 1 or 2;
  • R 2 is none, hydrogen, hydroxyl, cyano or C 1-6 alkyl
  • R 3 is , heteroaryl, heteroaryl-C 1-3 alkyl, heterocyclyl, or heterocyclyl C 1-3 alkyl;
  • R 4 is none, hydrogen, hydroxyl, C 1-6 alkyl or amine
  • n 0, 1, 2 or 3;
  • n 0, 1, 2, 3, 4 or 5;
  • each of R 5 is independently halo, C 1-6 alkyl, C 2-6 alkenyl, C 1-6 alkoxy, C 1-3 alkoxy-C 1-3 alkyl, C 1-6 hydroxyalkyl, C 1-6 dihydroxyalkyl, C 1-6 haloalkyl unsubstituted or optionally substituted with hydroxy, C 3-7 cycloalkyl, C 1-6 alkyloxo, cyano, nitro, carboxy, C 1-6 alkoxycarbonyl or -Z-(CH 2 ) p -R 6 ;
  • p 0, 1, 2, 3, 4, 5 or 6;
  • Z is -O-, -S(O) q -, -NR 7 -, -CONR 7 -, -CHR 7 - or none;
  • q 0, 1 or 2;
  • r 0, 1 or 2;
  • R 7 is hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, C 1-3 alkyl-C 3-6 cycloalkyl or C 1-3 alkoxy-C 1-3 alkyl;
  • R 8 is hydrogen, C 1-6 alkyl, C 1-6 alkoxy, amino, C 1-6 alkylamino, C 1-6 aminoalkyl, heterocyclyl, C 3-6 cycloalkyl, C 1-3 alkyl-C 3-6 cycloalkyl, C 1-6 alkyloxo or C 1-3 alkoxy-C 1-3 alkyl;
  • each of R 9 and R 10 is independently hydrogen, C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, C 1-3 alkyl-C 3-6 cycloalkyl, C 1-3 alkoxy-C 1-3 alkyl or -(SO 2 )-C 1-3 alkyl;
  • each of the heteroaryls may be a 5- to 10-membered single or fused ring containing one or more heteroatom selected from the group consisting of N, O, S and a combination thereof, and each of the heterocycles may be a 3- to 10-membered single or fused ring containing one or more heteroatom selected from the group consisting of N, O, S and a combination thereof;
  • each of the cycloalkyls and heterocyclyls may optionally be substituted with one to three substituents selected from the group consisting of C 1-6 alkyl, hydroxyl, oxo, C 1-6 hydroxyalkyl, halo, cyano, nitro, C 1-6 haloalkyl, C 1-6 alkoxy, formyl, C 1-6 alkylformyl, carboxy, C 1-6 alkylcarboxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, carbamoyl, C 1-6 alkylcarbamoyl, di(C 1-6 alkyl)carbamoyl and C 1-3 alkoxy-C 1-3 alkyl; and
  • each of the aryls and heteroaryls may optionally be substituted with one to three substituents selected from the group consisting of C 1-6 alkyl, C 1-6 alkoxy, C 1-3 alkoxy-C 1-3 alkyl, C 1-6 hydroxyalkyl, C 1-6 haloalkyl, halo, cyano, pyrazinyl, hydroxy, oxo, nitro, formyl, C 1-6 alkylformyl, carboxy, C 1-6 alkylcarboxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, carbamoyl, C 1-6 alkylcarbamoyl, di(C 1-6 alkyl)carbamoyl and C 1-6 alkylsulfonyl.
  • V is N or CH
  • R 1 is hydrogen, C 1-6 alkyl, C 1-6 hydroxyalkyl, or C 1-6 dihydroxyalkyl;
  • each of W and X is independently CH or CH 2 ;
  • Y is N or C
  • l 0, 1 or 2.
  • V is N or CH
  • R 1 is hydrogen or C 1-6 alkyl
  • each of W and X is independently CH or CH 2 ;
  • Y is N or C
  • l 0, 1 or 2;
  • R 2 is none, hydrogen or hydroxyl
  • R 3 is or heteroaryl
  • R 4 is none or hydrogen
  • n 0;
  • n 1, 2 or 3;
  • each of R 5 is independently halo, C 2-6 alkenyl, C 1-6 alkoxy, C 1-3 alkoxy-C 1-3 alkyl, C 1-6 hydroxyalkyl, C 1-6 dihydroxyalkyl or -Z-(CH 2 ) p -R 6 ;
  • p 0, 1, 2, 3 or 5;
  • Z is -O-, -NR 7 - or none
  • R 7 is hydrogen
  • R 8 is hydrogen, C 1-6 alkyl, C 1-6 alkoxy, amino, C 1-6 alkylamino, C 1-6 aminoalkyl or heterocyclyl;
  • each of R 9 and R 10 is independently hydrogen, C 1-6 alkyl, C 1-3 alkoxy-C 1-3 alkyl or -(SO 2 )-C 1-3 alkyl;
  • each of the heteroaryls may be a 5- to 10-membered single or fused ring containing one or more heteroatom selected from the group consisting of N, O, S and a combination thereof, and each of the heterocycles may be a 3- to 10-membered single or fused ring containing one or more heteroatom selected from the group consisting of N, O, S and a combination thereof;
  • each of the heterocyclyls may optionally be substituted with one to three substituents selected from the group consisting of C 1-6 alkyl, hydroxyl, amino, oxo, C 1-6 hydroxyalkyl and halo; and
  • each of the heteroaryls may optionally be substituted with one to three C 1-6 alkyl.
  • V is N or CH
  • R 1 is hydrogen or methyl
  • each of W and X is independently CH or CH 2 ;
  • Y is N or C
  • l is 1 or 2;
  • R 2 is none, hydrogen or hydroxyl
  • R 3 is or heteroaryl
  • R 4 is none or hydrogen
  • n 0;
  • n 1, 2 or 3;
  • each of R 5 is independently fluoro, vinyl, isoipropoxy, methoxyethyl, methoxypropyl, hydroxyethyl, 1,2-dihydroxyethyl, 2,3-dihydroxypropyl or -Z-(CH 2 ) p -R 6 ;
  • p 0, 1, 2, 3 or 5;
  • Z is -O-, -NR 7 - or none
  • R 7 is hydrogen
  • R 8 is hydrogen, methyl, amino, methylamino, or aminoethyl
  • each of R 9 and R 10 is independently hydrogen, methyl, ethyl or methoxyethyl
  • each of the heteroaryls may be a 5- to 10-membered single or fused ring containing one or more heteroatom selected from the group consisting of N, O, S and a combination thereof, and each of the heterocycles may be a 3- to 10-membered single or fused ring containing one or more heteroatom selected from the group consisting of N, O, S and a combination thereof;
  • each of the heterocyclyls may optionally be substituted with one to three substituents selected from the group consisting of methyl, fluoro, hydroxyl, amino and oxo; and
  • each of the heteroaryls may optionally be substituted with one to three methyl.
  • each of the aryls is phenyl or naphthyl
  • each of the heteroaryls may be selected from the group consisting of tetrazolyl, imidazolyl, pyridinyl, pyridazinyl, pyrimidyl, triazinyl, pyrrolyl, pyrazolyl, triazolyl, pyrazinyl, furyl, thienyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, furazanyl, oxazolyl, indolyl, isoindolyl, indazolyl, quinolinyl, isoquinolinyl, benzothiazolyl, benzoxazolyl, benzofuranyl, benzoimidazolyl, benzotriazolyl and azaindolyl; and
  • each of the heterocyclyls may be selected from the group consisting of tetrahydropyranyl, tetrahydrofuranyl, dihydrofuranyl, dihydropyranyl, dioxanyl, dithianyl, dioxolanyl, imidazolidinyl, imidazolinyl, pyrrolinyl, oxetanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxothiomorpholinyl, dioxotetrahydrothiophenyl, dioxothiolanyl, oxopiperidinyl, oxopyrrolidinyl and oxo-oxazolidinyl.
  • each of the aryls is phenyl
  • each of the heteroaryls is tetrazolyl or imidazolyl
  • each of the heterocyclyls is tetrahydrofuranyl, oxetanyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl.
  • each of the heterocyclyls is tetrahydrofuranyl, oxetanyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, 4-methylpiperazinyl, 4-methyl-2-oxopiperazinyl, 3-hydroxypyrrolidinyl, 2-hydroxymethylpyrrolidinyl, N-methylpyrrolidinyl, 4-hydroxypiperidinyl, 4-hydroxy-4-methylpiperidinyl, 4-aminopiperidinyl, 2-oxopiperidinyl, 2,6-dimethylpiperidinyl or 4,4-difluoropiperidinyl.
  • the compound may be any organic compound. More Preferably, the compound may be any organic compound.
  • the compound of the present invention may be prepared by synthesizing an imidazotriazinone derivative as an intermediate which serves as the core parent structure from a starting material, ethyl bromopyruvate, via a series of reactions and then introducing additional substituent by a substitution reaction using a reactive chloride group.
  • the following reaction scheme is presented as an exemplary preparation method of the compound of the present invention.
  • the method for preparing the compound of the present invention is not limited thereto and a method known in the art may be employed with appropriate modification, if necessary.
  • R 1 is as defined in Chemical Formula 1.
  • aminopyruvate derivative ( 2 ) by reacting ethyl bromopyruvate with dibenzylamine, the formed aminopyruvate derivative was reacted with aminoguanidine bicarbonate (IUPAC name: hydrazinecarboximidamide carbonate) or 2-aminoacetimidamid bicarbonate to form a triazinone ring (2). Then, via hydrosoluble elimination reaction using a palladium catalyst, a benzyl group was eliminated from the product by hydrogenation. Here, the product was formed in the form of a hydrocholoride salt ( 3 ). Further, through a reaction with an active ester compound, the product was amidated ( 4 ).
  • aminoguanidine bicarbonate IUPAC name: hydrazinecarboximidamide carbonate
  • 2-aminoacetimidamid bicarbonate 2-aminoacetimidamid bicarbonate
  • the active ester compound may be C 1-7 alkanoic anhydride, C 2-7 hydroxyalkanoic anhydride, C 2-7 dehydroxyalkanoic anhydride, 1,1-dioxotian-4-carboxylic anhydride, or tetrahydropyran-4-carboxylic anhydride. More preferably, the active ester compound is C 1-7 alkanoic anhydride, although not limited thereto.
  • the product may form a compound with a structure of imidazotriazinone ( 5 ) which serves as the parent structure of the present invention via a cyclization reaction by POCl 3 .
  • the product contains an amino group substituted into a triazinone ring and may be reacted with a chlorine-containing compound in the presence of tert-butyl nitrite (TBN) to replace the amino group with highly reactive chloride.
  • TBN tert-butyl nitrite
  • the substitution reaction which replaces the amino group with chloride may be performed by reacting with pyridine hydrochloride using dichloromethane as a solvent or reacting with antimony trichloride using 1,2-dichloroethane as a solvent in the presence of TBN.
  • reacting with antimony trichloride using 1,2-dichloroethane as a solvent in the presence of TBN may be performed at a higher yield, but is not limited thereto.
  • Additional amination reaction can be performed to the imidazotriazinone derivative substituted with chloro group ( 6 ) to obtain a target compound of the present invention, imidazotriazinone derivative ( 7 ).
  • the amination reaction can be accomplished by reaction of an amine compound comprising a suitable substituent for a desired target compound with DIPEA at 150°C for 0.5 hour in an alcohol solvent such as isopropanol or ethanol.
  • the compound of the present invention may be prepared by synthesizing an imidazopyrazinone derivative, an intermediate which constitutes the core parent structure of the compound of the present invention, from 2,6-dichloropyrazine as a starting material, and then introducing additional substituent(s) through substitution reaction at reactive chloro group by a series of reactions described below.
  • the method for preparing the compound of the present invention is not limited thereto and a method known in the art may be employed with appropriate modification, if necessary.
  • the triazolopyridinone derivative compound ( 8' ) as the target compound of the present invention may be obtained from the intermediate compound ( 6' ) by conducting amination according to the following reaction scheme and, optionally, carrying out deprotection following the amination if necessary.
  • the amination may be conducted via Buchwald reaction of the intermediate to react with an amine compound containing a substituent suitable for the desired target compound, in a dioxane or toluene solvent.
  • the reaction may be carried out at 110°C for 12 to 24 hours.
  • the deprotection may be accomplished by reaction in methanol solvent under 10% Pd/C catalyst to remove a benzyl group.
  • the present invention provides a pharmaceutical composition for treating or preventing a tankyrase-related disease, which contains the compound of the present invention, a tautomer thereof, a stereoisomer thereof and their mixture or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the compound of the present invention, the tautomer thereof, a stereoisomer thereof and their mixture, or the pharmaceutically acceptable salt thereof may exhibit activity of inhibiting activities of tankyrase 1, tankyrase 2 or both.
  • a pharmaceutical composition comprising the compound of the present invention as an active ingredient may be usefully used for the prevention or treatment of a cancer, multiple sclerosis (MS), a cardiovascular disease, central nervous system injury and an inflammatory disease.
  • the cancer may be selected from a group consisting of a cancer of head, neck, eyes, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lungs, colon, rectum, stomach, prostate, bladder, uterine, cervix, breast, ovaries, testices or other reproductive organs, skin, thyroid, blood, lymph nodes, kidneys, liver, pancreas, brain or central nervous system, a solid tumor, a blood-borne tumor, etc.
  • the tankyrase-related disease that can be prevented or treated using the pharmaceutical composition of the present invention may be colorectal cancer including colon cancer and rectal cancer, breast cancer, lung cancer or haematological malignancy, although not limited thereto.
  • the compound of the present invention may exist in the form of a pharmaceutically acceptable salt.
  • An acid addition salt formed by a pharmaceutically acceptable free acid is useful as the salt.
  • pharmaceutically acceptable salt used in the present invention refers to any organic or inorganic addition salt of the compound represented by Chemical Formula 1 which is at such a concentration that is relatively nontoxic to a patient and has a harmless effective action, and adverse side effects from the salt does not counteract benefits of the compound.
  • the acid addition salt may be prepared according to a commonly employed method, for example, by dissolving the compound in an excess amount of an aqueous acid solution and precipitating the salt using a water-miscible organic solvent, e.g., methanol, ethanol, acetone or acetonitrile. After heating the compound with an equimolar acid or alcohol (e.g., glycol monomethyl ether) in water, the mixture may be dried via evaporation, or the precipitated salt may be filtered through suction.
  • a water-miscible organic solvent e.g., methanol, ethanol, acetone or acetonitrile.
  • an equimolar acid or alcohol e.g., glycol monomethyl ether
  • a free acid may be an organic acid or an inorganic acid.
  • an inorganic acid hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, stannic acid, etc. may be used and, as an organic acid, methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic and, ascorbic acid, carbonic acid, vanillic acid, hydroiodic acid, etc. may be used, although not limited thereto.
  • a pharmaceutically acceptable metal salt may be prepared using a base.
  • An alkali metal salt or an alkaline earth metal salt may be obtained, for example, by dissolving the compound in an excess amount of an alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering an undissolved compound salt and then evaporating and drying the filtrate.
  • a sodium, potassium or calcium salt may be pharmaceutically suitable, although not limited thereto.
  • a corresponding silver salt may be obtained by reacting the alkali metal or alkaline earth metal salt with an appropriate silver salt (e.g., silver nitrate).
  • the pharmaceutically acceptable salt of the compound of the present invention includes a plausible acidic or basic salt of the compound of Chemical Formula 1.
  • the pharmaceutically acceptable salt includes sodium, calcium and potassium salts having a hydroxyl group.
  • hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate) salts having an amino group may be included as other pharmaceutically acceptable salts. They may be prepared by salt preparation methods known in the art.
  • the pharmaceutically acceptable salt of imidazotriazinone or imidazopyrazinone derivative of the present invention may be any pharmaceutically acceptable salt of imidazotriazinone or imidazopyrazinone derivatives which exhibit inhibitory activity against tankyrase 1 and/or tankyrase 2, which is equivalent to that of imidazotriazinone or imidazopyrazinone derivative compounds, without limitation.
  • prevention refers to any act of inhibiting or retarding the onset, development and recurrence of tankyrase-related diseases by administering the composition of the present invention
  • treatment refers to any act of ameliorating or improving symptoms of the diseases by administering the composition of the present invention.
  • composition of the present invention can prevent or treat tankyrase-related disease by inhibiting the activity of tankyrase 1 and/or tankyrase 2 and thereby regulating cell death proliferation and/or metastasis, it can be usefully used to prevent or treat a diseased induced by abnormal activity of tankyrase 1 and/or tankyrase 2.
  • the pharmaceutical composition according to the present invention may contain 0.1 wt% to 75 wt%, more preferably 1 wt% to 50 wt%, of the compound represented by Chemical Formula 1, the tautomer thereof, the stereoisomer thereof and their mixture or the pharmaceutically acceptable salt thereof as an active ingredient, based on the total weight of the composition.
  • composition of the present invention may further contain a pharmaceutically acceptable carrier, diluent, or excipient, and may be prepared into various formulations including oral formulations such as powder, granule, tablet, capsule, suspension, emulsion, syrup, aerosol, etc., sterile injection solution, etc. according to commonly employed methods. It may be administered orally or via various routes including intravenous, intraperitoneal, subcutaneous, rectal and topical routes.
  • a pharmaceutically acceptable carrier such as powder, granule, tablet, capsule, suspension, emulsion, syrup, aerosol, etc., sterile injection solution, etc. according to commonly employed methods. It may be administered orally or via various routes including intravenous, intraperitoneal, subcutaneous, rectal and topical routes.
  • the suitable carrier, excipient, or diluent that can be contained in the composition may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, etc.
  • the composition of the present invention may further contain a filler, an antiaggregant, a lubricant, a wetting agent, a fragrance, an emulsifier, a preservative, etc.
  • Solid formulations for oral administration may include tablet, pill, powder, granule, capsule, etc. These solid formulations may be prepared by mixing at least one excipient, e.g., starch, calcium carbonate, sucrose, lactose, gelatin, etc., in the composition. In addition to a simple excipient, a lubricant such as magnesium stearate and talc may be used.
  • excipient e.g., starch, calcium carbonate, sucrose, lactose, gelatin, etc.
  • a lubricant such as magnesium stearate and talc may be used.
  • Liquid formulations for oral administration may be exemplified by suspension, solution for internal application, emulsion, syrup, etc.
  • various excipients such as a wetting agent, a sweetener, an aromatic, a preservative, etc. may be included.
  • Formulations for parenteral administration may include sterilized aqueous solution, non-aqueous solution, suspension, emulsion, lyophilizate and suppository.
  • non-aqueous solution or suspension propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, etc. may be used.
  • injectable formulations may contain commonly used additives such as a solubilizer, an isotonizing agent, a suspending agent, an emulsifier, a stabilizer, a preservative, etc.
  • composition of the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount refers to an amount which is sufficient to treat a disease at a reasonable benefit/risk ratio applicable for medical treatment without causing side effects.
  • the level of effective dosage may be determined based on the health condition of a patient, a kind of disease and severity thereof, drug activity, sensitivity to the drug, administration method, administration time, administration route, rate of excretion, treatment period, drugs used in combination or simultaneously and other factors well known in the medical field.
  • the composition of the present invention may be administered as an independent therapeutic agent or in combination with other therapeutic agent(s) sequentially or simultaneously. Also, it may be administered in the form of a single dose or multidoses. It is important to administer an amount that can derive the maximum effects with the minimum amount with no side effect in consideration of all the above-described factors, which can be easily determined by those skilled in the art.
  • the effective amount of the compound in the composition of the present invention may vary depending on the age, sex and body weight of a patient. In general, an amount of 1 mg to 100 mg, preferably 5 mg to 60 mg, per kg body weight may be administered once a day, once in two days or 1 to 3 times a day. However, since the administration dosage can be increased or decreased depending on the administration route, severity of disease, sex, body weight, and age, etc., it does not limit the scope of the present invention by any means.
  • the present invention also provides a method for preventing or treating a tankyrase-related disease of a subject, which includes administering the compound represented by Chemical Formula 1, the tautomer thereof, the stereoisomer thereof and their mixture or the pharmaceutically acceptable salt thereof to the subject in need thereof.
  • the term "subject” refers to an animal in which a tankyrase-related disease has occurred or is likely to occur, including human, monkey, cow, horse, sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit or guinea pig.
  • the disease may be effectively prevented or treated by administering the pharmaceutical composition of the present invention to the subject.
  • the pharmaceutical composition of the present invention may be administered in combination with existing therapeutic agent.
  • the term "administration" refers to introduction of a desired substance to a patient in any appropriate way.
  • the composition of the present invention may be administered via any general administration route as long as it can reach a target tissue.
  • the composition may be administered intraperitoneally, intravenously, intramuscularly, subcutaneously, intradermally, orally, topically, intranasally, intrapulmonarily or rectally, although not limited thereto.
  • the pharmaceutical composition of the present invention may be administered by any apparatus that can deliver an active substance to a target cell.
  • Preferred administration methods and formulations include intravenous injection, subcutaneous injection, intradermal injection, intramuscular injection, bolus injection, etc.
  • the injection may be prepared using water-based solutions such as physiological saline, Ringer's solution, etc., or non-water-based solutions such as vegetable oils, higher fatty acid esters (e.g., ethyl oleate), alcohols (e.g., ethanol, benzyl alcohol, propylene glycol, glycerin, etc.), and may contain a pharmaceutical excipient such as a stabilizer for preventing denaturation (e.g., ascorbic acid, sodium bisulfife, sodium pyrosulfite, BHA, tocopherol, EDTA, etc.), an emulsifier, a buffer for pH control, a preservative for inhibiting microbial growth (e.g., phenylmercuric nitrate, thimerosal, benzalkonium chloride, phenol, cresol, benzyl alcohol, etc.), etc.
  • a pharmaceutical excipient such as a stabilizer for preventing denaturation (e.
  • the term "therapeutically effective amount" used in combination with an active ingredient refers to an amount of the imidazotriazinone or imidazopyrazinone derivative compound, the tautomer thereof, the stereoisomer thereof and their mixture or the pharmaceutically acceptable salt thereof which is effective in preventing or treating a target disease.
  • the pharmaceutical composition of the present invention may further comprise a drug used and known for the prevention or treatment of a particular disease depending on a kind of a disease to be prevented or treated.
  • the composition when used for prevention or treatment of a cancer, may further contain, in addition to the imidazotriazinone or imidazopyrazinone derivative compound, the tautomer thereof, the stereoisomer thereof and their mixture or the pharmaceutically acceptable salt thereof as the active ingredient, a known anti-cancer agent.
  • other therapies may be used in combination to treat the disease, which include chemotherapy, radiation therapy, hormone therapy, bone marrow transplantation, stem cell replacement therapy, other biological therapies, immunotherapy, etc., although not limited thereto.
  • anti-cancer agents examples include a DNA alkylating agent such as mechlorethamine, chlorambucil, phenylalanine, mustard, cyclophosphamide, ifosfamide, carmustine (BCNU), lomustine (CCNU), streptozotocin, busulfan, thiotepa, cisplatin and carboplatin; an anti-cancer antibiotic such as dactinomycin (actinomycin D), doxorubicin (Adriamycin), daunorubicin, idarubicin, mitoxantrone, plicamycin, mitomycin C and bleomycin; and a plant alkaloid such as vincristine, vinblastine, paclitaxel, docetaxel, etoposide, teniposide, topotecan and iridotecan, etc., although not limited thereto.
  • a DNA alkylating agent such as mechlorethamine, chloramb
  • a novel imidazotriazinone or imidazopyrazinone derivative of the present invention can inhibit tankyrase 1 and/or tankyrase 2, it can be effectively used to treat or prevent a disease induced by overexpression or hyperactivation of tankyrases.
  • the intermediate I-2 was hydrogenated at rt for 48 h in 2 N HCl in EtOH using Pd/C (20 wt%) catalyst to afford 3-amino-6-(aminomethyl)-1,2,4-triazin-5(4H)-one dihydrochloride ( I-3 ; yield 98%).
  • the compound I-2A was prepared by the following sequence of reactions: O-alkylation used in Preparation Example 3.1, N-arylation used in Preparation Example 2.2, and Boc-group deprotection used in Preparation Example 2.5.
  • the allylic compound obtained in Preparation Example 8.4 was dihydroxylated by OsO 4 . Then, the desired product was afforded by removing the N-acetyl group under acidic conditions.
  • the vinyl group was introduced via the Stille coupling reaction employed in Preparation Example 8.3 using (vinyl)SnBu 3 .
  • the vinylic compound, obtained in Preparation Example 9.1, was dihydroxylated by OsO 4 . Then, the compound B was obtained by removing the N-acetyl group of the dihydroxylated compound under acidic conditions.
  • the desired product was prepared in analogously with the procedure in Preparation Example 11.1.
  • the desired product was synthesized by following reaction conditions similar to those used in Preparation Examples 11.8 and 11.9.
  • the desired product was synthesized by following reaction conditions similar to those used in Preparation Examples 11.8 and 11.9.
  • the desired product was synthesized by following reaction conditions similar to those used in Preparation Examples 11.8 and 11.9.
  • the desired product was synthesized by following reaction conditions similar to those used in Preparation Examples 11.8 and 11.9.
  • the aminated intermediate was prepared by reacting the compound (0.42 g, 1.00 mmol) obtained in Preparation Example 12.1 with Cs 2 CO 3 (0.98 g, 3 mmol) and 3-hydroxypyrrolidine (0.13 g, 1.5 mmol) and in DMF (5 mL). The intermediate was treated with 4 M HCl to remove the Boc-group of piperidine to afford the desired product (0.3 g).
  • the desired product was synthesized by a method similar to that used in Preparation Example 12.2.
  • Example 1 2 -(4-(2- Fluorophenyl ) piperazin -1- yl )-7- methylimidazo[1,5-f] [1,2,4]triazin-4(3H)-one
  • Example 2 2 -(4-(2,6- Difluoro -4-(2- methoxyethoxy )phenyl) piperazin -1-yl)-7-methylimidazo[1,5-f][1,2,4]triazin-4(3H)-one
  • Example 3 2 -(4-(4-( Benzyloxy )-2,6- difluorophenyl ) piperazin -1- yl )-7-methylimidazo[1,5-f][1,2,4]triazin-4(3H)-one
  • Example 4 2 -(4-(2,6- Difluoro -4-(2- morpholinoethoxy )phenyl) piperazin -1-yl)-7-methylimidazo[1,5-f][1,2,4]triazin-4(3H)-one
  • Example 6 2 -(4-(4-(2-( Dimethylamino ) ethoxy )-2,6-difluorophenyl)piperazin-1-yl)-7-methylimidazo[1,5-f][1,2,4]triazin-4(3H)-one
  • Example 7 2 -(4-(2,6- Difluoro -4-(2- hydroxyethoxy )phenyl) piperazin -1-yl)-7-methylimidazo[1,5-f][1,2,4]triazin-4(3H)-one
  • Step 1 tert-Butyl 4-(2,6-difluoro-4-hydroxyphenyl)piperazine-1-carboxylate was alkylated using a method similar to that described in Preparation Example 2.3 to afford tert-butyl 4-(4-(2-benzyloxy-ethoxy)-2,6-difluoro-phenyl)-piperazine-1-carboxylate.
  • the Boc-deprotected compound was obtained by treatment with HCl.
  • Step 2 A mixture of the amine (429 mg, 1.11 mmol) obtained in step 1, the intermediate I-6 (184 mg, 1.0 mmol), and DIPEA (174 mg, 1.35 mmol) in EtOH (3.0 mL) was heated under microwave heating conditions at 150°C for 30 min.
  • Step 3 To a solution in CH 2 Cl 2 :MeOH (1 mL:1 mL) of 2-(4-(2,6-difluoro-4-(2-benzyloxyethoxy)phenyl)piperazin-1-yl)-7-methylimidazo[1,5-f][1,2,4]triazin-4(3H)-one (105 mg, 0.21 mmol) obtained in step 2, 10% Pd/C (40 mg) was added, and the reaction mixture was stirred at rt for 24 h under hydrogen gas. The mixture was filtered through a Celite pad and concentrated under reduced pressure. The resulting solid was recrystallized in MeOH/Et2O to afford the desired product.
  • Step 1 A mixture of (S)-2-(tert-butoxycarbonylamino)propionic acid (24 mg, 0.129 mmol), the compound obtained in Example 7 (35 mg, 0.086 mmol), EDC ⁇ HCl (49 mg, 0.258 mmol), and HOBt (35 mg, 0.258 mmol) in CH 2 Cl 2 (2 mL) was stirred at 25°C for 17 h. The resulting mixture was concentrated under reduced pressure, and the residue was purified by column chromatography to afford the desired product (15 mg).
  • Step 2 To a solution in CH 2 Cl 2 (2 mL) of the compound obtained in Step 1 (15 mg, 0.026 mmol), 4 M HCl in dioxane (104 ⁇ L) was added. The solution was stirred at 25°C for 2 h. The resulting mixture was concentrated under reduced pressure to afford the desired product (13 mg).
  • Example 9 2 -(4-(4-(2,3- Dihydroxypropoxy )-2,6- difluorophenyl ) piperazin -1-yl)-7-methylimidazo[1,5-f][1,2,4]triazin-4(3H)-one
  • tert-Butyl 4-(2,6-difluoro-4-hydroxyphenyl)piperazin-1-carbonate was alkylated by treatment with glycidyl benzyl ether in MeCN in the presence of LiClO 4 . After removal of the Boc protecting group, the amine thus produced was reacted with the intermediate I-6 to afford the corresponding coupling product, which was debenzylated to afford the desired product.
  • Example 10 2 -(4-(2,6- Difluoro -4-( morpholinomethyl )phenyl) piperazin -1-yl)-7-methylimidazo[1,5-f][1,2,4]triazin-4(3H)-one
  • Example 12 2 -(4-(2,6- Difluoro -4-( oxetan -3- yloxy )phenyl) piperazin -1-yl)-7-methylimidazo[1,5-f][1,2,4]triazin-4(3H)-one
  • Example 13 2 -(4-(2,6- Difluoro -4-(1-hydroxyethyl)phenyl) piperazin -1-yl)-7-methylimidazo[1,5-f][1,2,4]triazin-4(3H)-one
  • Example 14 2 -(4-(2,6- Difluoro -4-(1- methoxyethyl )phenyl) piperazin -1-yl)-7-methylimidazo[1,5-f][1,2,4]triazin-4(3H)-one
  • Example 15 2 -(4-(2,6- Difluorophenyl ) piperazin -1- yl )-7-methylimidazo[1,5-f][1,2,4]triazin-4(3H)-one
  • Example 17 2 -(4-(2,6- Difluoro -4-(2- methoxyethoxy )phenyl)-4-hydroxypiperidin-1-yl)-7-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one
  • Example 18 2 -(4-(2,6- Difluoro -4-(2- methoxyethylamino )phenyl) piperazin -1-yl)-7-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one
  • Example 20 2 -(4-(4-(1,2- Dihydroxyethyl )-2,6- difluorophenyl ) piperazin -1-yl)-7-methylimidazo[1,5-f][1,2,4]triazin-4(3H)-one
  • Example 21 2 -(4-(4-(2,3- Dihydroxypropyl )-2,6- difluorophenyl ) piperazin -1-yl)-7-methylimidazo[1,5-f][1,2,4]triazin-4(3H)-one
  • Example 22 2 -(4-(1H- Tetrazol -5- yl ) piperidin -1- yl )-7- methylimidazo[1,5-f] [1,2,4]triazin-4(3H)-one
  • Example 23 7 -Methyl-2-(4-(2-methyl-2H-tetrazol-5-yl)piperidin-1-yl)imidazo[1,5-f][1,2,4]triazin-4(3H)-one
  • Example 27 2 -(4-(4-( Bis(2-methoxyethyl)amino )-2,6-difluorophenyl)piperazin-1-yl)-7-methylimidazo[1,5-f][1,2,4]triazin-4(3H)-one
  • Example 30 2 -(4-(2,6- Difluoro -4-(2- piperidin -1- yl ) ethoxy )-phenyl)-1,4-diazepan-1-yl)-7-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one
  • Step 1 tert-Butyl 4-(4-(benzyloxy)-2,6-difluorophenyl)diazepan-1-carboxylate was afforded using a method similar to that described in Preparation Example 2.2, except by reaction with Boc-diazepane instead of Boc-piperazine.
  • Step 2 4-(4-(Benzyloxy)-2,6-difluorophenyl)diazepane hydrochloride was afforded from the compound obtained in step 1 using a method similar to those described in Preparation Examples 2.3 to 2.6.
  • Step 3 The desired product was afforded by reacting the compound obtained in step 2 with the compound I-6, using a method similar to that described in Example 1.
  • Example 31 2 -(4-(4-(2- Azidoethoxy )-2,6- difluorophenyl ) piperazin -1- yl )-7-methylimidazo[1,5-f][1,2,4]triazin-4(3H)-one
  • Example 32 2 -(4-(4-(2- Aminoethoxy )-2,6- difluorophenyl ) piperazin -1- yl )-7-methylimidazo[1,5-f][1,2,4]triazin-4(3H)-one
  • Example 34 2 -(4-(4-(2-(4- Aminopiperidin -1- yl ) ethoxy )-2,6-difluorophenyl)piperazin-1-yl)-7-methylimidazo[1,5-f][1,2,4]triazin-4(3H)-one
  • Step 1 Following the general procedure of Example 1, the Cbz-protected compound was afforded by the reaction of the compound I-6 with the amine ( I-11G ).
  • Step 2 Following the general procedure of Example 32, the desired product was afforded using the compound obtained in Step 1.
  • Example 37 6 -(4-(2,6- Difluoro -4-(2- methoxyethoxy )phenyl) piperazin -1-yl)-3-methylimidazo[1,5-a]pyrazin-8(7H)-one
  • Step 1 A mixture of the compound I-13 (195 mg, 0.710 mmol), the amine I-2A (195 mg, 0.852 mmol), sodium tert-butoxide (204.6 mg, 2.130 mmol), BINAP (44.2 mg, 0.035 mmol), and Pd 2 (dba) 3 (32.5 mg, 0.133 mmol) in toluene was heated under microwave heating conditions at 150°C for 20 min. After cooling down to rt, the resulting mixture was filtered through a Celite pad. The mixture was diluted with EtOAc and washed with water. The organic layer was dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to afford the desired product.
  • Step 2 A solution in MeOH (0.68 mL) and EtOAc (0.2 mL) of the compound (104 mg, 0.204 mmol) obtained in step 1 was charged with 10% Pd/C (20 mg) and stirred under hydrogen gas for 24 h. The product was filtered through a Celite pad, and the filtrate was concentrated under reduced pressure and washed with ether to afford the desired product as a white solid.
  • Example 38 6 -(4-(2,6- Difluoro -4-(2- morpholinoethoxy )phenyl) piperazin -1-yl)-3-methylimidazo[1,5-a]pyrazin-8(7H)-one
  • Example 39 6 -(4-(2,6- Difluoro -4-(2-( piperidin -1-yl)ethoxy)phenyl)piperazin-1-yl)-3-methylimidazo[1,5-a]pyrazin-8(7H)-one
  • Example 40 6 -(4-(4-(2-( Dimethylamino ) ethoxy )-2,6-difluorophenyl)piperazin-1-yl)-3-methylimidazo[1,5-a]pyrazin-8(7H)-one
  • Example 41 6 -(4-(2,6- Difluoro -4-( morpholinomethyl )phenyl) piperazin -1-yl)-3-methylimidazo[1,5-a]pyrazin-8(7H)-one
  • Example 42 6 -(4-(2,6- Difluoro -4-((4- methylpiperazin -1-yl)methyl)phenyl)piperazin-1-yl)-3-methylimidazo[1,5-a]pyrazin-8(7H)-one
  • Example 43 6 -(4-(2,6- Difluoro -4-( oxetan -3- yloxy )phenyl) piperazin -1-yl)-3-methylimidazo[1,5-a]pyrazin-8(7H)-one
  • Example 44 6 -(4-(2,6- Difluoro -4-(1- methoxyethyl )phenyl) piperazin -1-yl)-3-methylimidazo[1,5-a]pyrazin-8(7H)-one
  • Example 46 6 -(4-(2,6- Difluoro -4-(2-( pyrrolidin -1-yl)ethoxy)phenyl)piperazin-1-yl)-3-methylimidazo[1,5-a]pyrazin-8(7H)-one
  • Example 48 6 -(4-(2,6- Difluoro -4-(3-( piperidin -1-yl)propoxy)phenyl)piperazin-1-yl)-3-methylimidazo[1,5-a]pyrazin-8(7H)-one
  • Example 37 Following the general procedure in Example 37, the desired product was afforded using the amine prepared in Example 26.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un nouveau dérivé imidazotriazinone ou imidazopyrazinone, un tautomère de celui-ci, un stéréoisomère de celui-ci et leur mélange, ou un sel pharmaceutiquement acceptable de celui-ci ; et une composition pharmaceutique pour la prévention ou le traitement d'une maladie liée à la tankyrase, qui contient les dérivés selon l'invention en tant qu'ingrédient actif.
PCT/KR2015/007220 2014-07-11 2015-07-10 Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation WO2016006975A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP15818456.4A EP3166946A4 (fr) 2014-07-11 2015-07-10 Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation
US15/325,692 US10179785B2 (en) 2014-07-11 2015-07-10 Imidazotriazinone or imidazopyrazinone derivatives, and use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2014-0087799 2014-07-11
KR20140087799 2014-07-11
KR1020150068368A KR20160007347A (ko) 2014-07-11 2015-05-15 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도
KR10-2015-0068368 2015-05-15

Publications (2)

Publication Number Publication Date
WO2016006975A2 true WO2016006975A2 (fr) 2016-01-14
WO2016006975A3 WO2016006975A3 (fr) 2016-07-21

Family

ID=55065061

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/007220 WO2016006975A2 (fr) 2014-07-11 2015-07-10 Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation

Country Status (1)

Country Link
WO (1) WO2016006975A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016147659A1 (fr) * 2015-03-16 2016-09-22 Sumitomo Dainippon Pharma Co., Ltd. Dérivé imidazolo bicyclique
CN106496056A (zh) * 2016-10-18 2017-03-15 中国人民解放军63975部队 一种芳基酰胺类化合物的合成方法
CN107286169A (zh) * 2016-04-05 2017-10-24 山东轩竹医药科技有限公司 端锚聚合酶抑制剂
EP3733206A4 (fr) * 2017-12-27 2021-12-01 Japanese Foundation For Cancer Research Agent anticancéreux
GB2632307A (en) * 2023-08-02 2025-02-05 Duke Street Bio Ltd PARP1 inhibitor compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201490272A1 (ru) * 2011-07-13 2014-05-30 Новартис Аг Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
SG11201403909RA (en) * 2012-01-26 2014-10-30 Lundbeck & Co As H Pde9 inhibitors with imidazo triazinone backbone
PE20142186A1 (es) * 2012-03-28 2014-12-29 Merck Patent Gmbh Derivados biciclicos de pirazinona
AR091271A1 (es) * 2012-06-07 2015-01-21 Hoffmann La Roche Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa
WO2013182546A1 (fr) * 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Inhibiteurs de tankyrase à base de pyrazolopyrimidone et de pyrazolopyridone
BR112014032053A2 (pt) * 2012-06-20 2017-06-27 Hoffmann La Roche composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016147659A1 (fr) * 2015-03-16 2016-09-22 Sumitomo Dainippon Pharma Co., Ltd. Dérivé imidazolo bicyclique
CN107286169A (zh) * 2016-04-05 2017-10-24 山东轩竹医药科技有限公司 端锚聚合酶抑制剂
CN107286169B (zh) * 2016-04-05 2020-11-24 北京四环制药有限公司 端锚聚合酶抑制剂
CN106496056A (zh) * 2016-10-18 2017-03-15 中国人民解放军63975部队 一种芳基酰胺类化合物的合成方法
EP3733206A4 (fr) * 2017-12-27 2021-12-01 Japanese Foundation For Cancer Research Agent anticancéreux
GB2632307A (en) * 2023-08-02 2025-02-05 Duke Street Bio Ltd PARP1 inhibitor compounds
WO2025026745A1 (fr) * 2023-08-02 2025-02-06 Duke Street Bio Limited Composés inhibiteurs de parp1

Also Published As

Publication number Publication date
WO2016006975A3 (fr) 2016-07-21

Similar Documents

Publication Publication Date Title
WO2019190259A1 (fr) Nouveau dérivé de sulfonamide ayant un effet inhibiteur sur la mutation du récepteur du facteur de croissance épidermique
EP3166945A2 (fr) Nouveaux dérivés triazolopyrimidinone ou triazolopyridinone et leur utilisation
WO2020171606A1 (fr) Nouveau composé hétérocyclique et utilisation associée
WO2017188694A1 (fr) Composé hétéroaryle comprenant de l'azote et son utilisation
WO2022139304A1 (fr) Nouveau composé dérivé de quinazoline en tant qu'inhibiteur de sos1, et son utilisation
EP2906558A1 (fr) Bloqueurs de canal sodique, leur procédé de préparation et leur utilisation
WO2016006975A2 (fr) Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation
WO2019054766A1 (fr) Composé dérivé de pyrazole et son utilisation
WO2014109530A1 (fr) Dérivé 2-(phényléthynyl)thiéno[3,4-b]pyrazine, et composition pharmaceutique comprenant ce dérivé et destinée à la prévention ou au traitement du cancer
WO2021145655A1 (fr) Nouveau dérivé de pyrazole
WO2011122815A2 (fr) Nouveaux dérivés de quinoxaline
WO2016006974A2 (fr) Nouveaux dérivés triazolopyrimidinone ou triazolopyridinone et leur utilisation
WO2018021826A1 (fr) Nouveau dérivé de pyrimidine-2,4-diamine et composition pharmaceutique pour la prévention ou le traitement du cancer contenant celui-ci comme ingrédient actif
WO2016093554A2 (fr) Nouveau dérivé de 4-(aryl)-n-(2-alkoxythiéno[3,2-b]pyrazin-3-yl)-pipérazine-1-carboxamide et effet antiprolifératif de celui-ci
WO2021256899A1 (fr) Nouveau composé hétérocyclique fusionné de dicyanure de carbonohydrazonoyle et son utilisation
WO2020096416A1 (fr) Composé inhibant la liaison yap-tead et composition pharmaceutique pour prévenir ou traiter le cancer contenant ledit composé en tant que principe actif
WO2010032986A2 (fr) Nouveaux dérivés de 5-(4-aminophenyl)-isoquinoline, leurs sels pharmaceutiquement acceptables, procédé de production associé et composition contenant les dérivés comme principe actif pour la prophylaxie et le traitement d'états pathologiques induits par l'hyperactivité de la kinase raf
EP3166946A2 (fr) Nouveaux dérivés imidazotriazinone ou imidazopyrazinone et leur utilisation
WO2022103149A1 (fr) Nouveau dérivé de carbazole et composition pharmaceutique pour la prévention ou le traitement du cancer le comprenant en tant que principe actif
WO2022010328A1 (fr) 1-alkyl-5-arylidène-2-sélénooxoimidazolidine-4-one et son dérivé, son procédé de préparation et composition le comprenant pour prévenir, soulager ou traiter des maladies neurodégénératives
WO2021194144A1 (fr) Nouveau dérivé de pyrimidine, et composition pour la prévention ou le traitement de maladies neurodégénératives et du cancer, comprenant celui-ci
WO2021040502A1 (fr) Dérivé d'imidazopyridine et composition pharmaceutique le comprenant en tant que principe actif
WO2017131500A1 (fr) Nouveau composé ayant une activité inhibitrice de hsp90 ou sel pharmaceutiquement acceptable de celui-ci, et utilisation médicale de celui-ci
WO2021080346A1 (fr) Nouveau dérivé de pyridinyltriazine ayant une activité inhibitrice de la protéine kinase, et composition pharmaceutique pour la prévention, l'amélioration ou le traitement du cancer le comprenant
WO2025005367A1 (fr) Nouveau composé hétéroaryl-carbonohydrazonoyl dicyanure substitué par hétérocycle saturé et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15818456

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15325692

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2015818456

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015818456

Country of ref document: EP